OncologyHeader
Areas of Interest
Oncology
Transform Cancer Therapeutics

Cancer encompasses a plurality of diseases caused by a variety of genetic and epigenetic factors. As such, targeted or personalized approaches to treatment are needed to address the root cause of specific cancers. Our ever-growing understanding of gene and signalling networks around various forms of cancer are providing new targets for the field and driving innovative new treatments. Genetic medicine approaches are often the only way to address these new targets, and promise to drastically improve outcomes and reduce side effects.



These approaches include:

 

  • MicroRNA mimics and other RNA interference approaches
  • Messenger RNA therapeutics
  • Cancer Vaccines
  • CAR T-cell therapy and other cell therapies


Oncology_2


Precision NanoSystems is uniquely positioned to provide a suite of solutions including formulation and manufacturing expertise and manufacturing technology to support development of nucleic acid based therapeutics from discovery to manufacturing.

Examples
NanoAssemblr Technology is used by innovative research institutes, top pharmaceutical companies and disruptive biotech companies to develop gene-based therapies for cancer.





Unlocking the Immune System



Researchers at MD Anderson and Arcturus Therapeutics describe using microRNA to activate the immune system against glioma - a devastating brain cancer. In previous work, MD Anderson researchers discovered the microRNA miR-124 was drastically suppressed in glioma compared to healthy neurons, and their work identified a link to how glioma evades the immune system. In this work, published in the March 2017 issue of the journal Neuro-Oncology, the authors encapsulated miR-124 mimics into lipid nanoparticles (LNPs) using NanoAssemblr Technology. Treating glioma-bearing murine models with miR-124-LNPs unleashed the immune system to fight glioma. This not only improved survival, but also imparted lasting protection from a second glioma challenge. Additionally, this formulation acts on peripheral blood mononuclear cells and does not need to cross the blood brain barrier to be effective. This constitutes an exciting immuno-oncology treatment for glioma that provides lasting protection against relapse with a single treatment, while proving to be safe in multiple species.

Read more

2017 Yaghi - Immune modulatory nanoparticle therapeutics for intracerebral glioma






Selectively Programming Cancer Cell Death



Apoptotic proteins can be used to signal cells to self-destruct. The challenge in using them for cancer therapy has been selectively targeting these signals exclusively to cancer cells without harming healthy cells. In a 2018 paper published in the journal Nucleic Acid Therapeutics, researchers at Moderna Therapeutics report overcoming this challenge. Their approach involved delivering mRNA encoding apoptotic proteins and delivering these to the liver using lipid nanoparticles formulated with NanoAssemblr technology. To control expression of the toxic protein, they analyzed differences in microRNA (miRNA) expression levels between healthy and cancerous liver cells and incorporated miRNA binding sites into their mRNA sequence. When the mRNA encoding the toxic protein is taken up by healthy cells, endogenous miRNAs bind to them, marking them for destruction through the RNA interference pathway before the protein can be expressed. In cancerous cells where these miRNAs are down regulated, the delivered mRNA is translated into toxic proteins. Hence tumour cells are selectively programmed to self-destruct. This constitutes a highly selective way to express exogenous proteins in cancer cells, opening new avenues for treatment.

Read more.

2018 JainThumb

Rapid, efficient development of nucleic acid therapeutics
RNA medicines are the next generation of cancer therapeutics, and lipid nanoparticles are at the forefront of delivery technologies.

Learn More
Nucleic Acid Lipid Nanoparticle LNP
Manufacturing Technology

NanoAssemblr technology is trusted by over 70% of top pharmaceutical companies, 80+ innovative biotech companies and 70+ renowned research institutes across all stages of nanomedicine development.

Nanoparticle Technology

Our reagents and transfection kits allow research access to lipid nanoparticle formulations featuring ionizable lipids similar to those in clinically validated formulations. These offer high encapsulation and transfection efficiency with no observed toxicity in numerous primary cell types and in vivo models.

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Oncology Resources

Webinar

April 26, 2016

Application of Microfluidic Mixing for Generating Limit Size Nanoparticles

Read More

Video

July 16, 2017

MicroRNA-Based Therapeutics in Cancer - Frank Slack, Harvard Medical School

Read More

Publication - Summary

June 19, 2012

The Journal of Physical Chemistry C, Nanomaterials and Interfaces

Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core

Leung AKK, Hafez IM, Baoukina S, Belliveau NM, Zhigaltsev IV, Afshinmanesh E, Tieleman DP, Hansen CL, Hope MJ, Cullis PR

Read More

Publication - Abstract

November 01, 2016

Canadian Journal of Chemistry

Branched-Chain and Dendritic Lipids for Nanoparticles

Meanwell MW, O’Sullivan C, Howard P, Fyles TM

Read More

Publication - Abstract

August 29, 2017

Journal of Liposome Research

Microfluidic preparation of drug-loaded PEGylated Liposomes, and the Impact of Liposome Size on Tumour Retention and Penetration

Dong YD, Tchung E, Nowell C, Kaga S, Leong N, Mehta D, Kaminskas LM, Boyd B

Read More

Publication - Abstract

August 22, 2017

Leukemia

RNA Interference Efficiently Targets Human Leukemia Driven by a Fusion Oncogene in Vivo

Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Kuchenbauer F, Sajti L, Barchanski A, Lindner R, Noyan F, Sühs KW, Grote-K...

Read More
Resource Center
MENU
X